VivoSeq
Other

PSMA PET

0

Pipeline Programs↗

4

Active Trials↗

2

Companies Involved↗

PSMA PET is an early-stage landscape with 0 programs across 2 companies. The most active players are Telix Pharmaceuticals (Innovations) Pty Limited, Novartis.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Telix Pharmaceuticals (Innovations) Pty Limited

0 programs

PreclinicalNovartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Recruiting3 · 60%
Terminated1 · 20%
Active, not recruiting1 · 20%

Clinical Trials

Trial Activity

PSMA PET Combined With MRI for the Detection of PCa
Recruiting·TTelix Pharmaceuticals (Innovations) Pty Limited·Phase 3·NCT07052214·204 enrolled
PSMA PET and MRI in Gynecological Cancers
Terminated·UUniversity of Wisconsin, Madison·Phase 2·NCT03302156·15 enrolled
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
Recruiting·—·Phase 4·NCT06099093·30 enrolled
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Active, not recruiting·Novartis logoNovartis·Phase 2·NCT05849298·49 enrolled
68Ga-PSMA PET/CT for Ra223 Assessment
Recruiting·—·N/A·NCT04951817·52 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)